The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
cPLA2α在类二十烷酸生物合成和伤口愈合中的作用和机制调节
基本信息
- 批准号:10644976
- 负责人:
- 金额:$ 45.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-01-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAccelerationAgeAgingAgonistAnabolismAnti-Inflammatory AgentsArachidonic AcidsBindingBiochemicalBiological MarkersCRISPR/Cas technologyCellsComplexCoupledCytosolic Phospholipase A2DataDermalDevelopmentDinoprostoneEicosanoid ProductionEicosanoidsEndotheliumEnzymesEtiologyExhibitsFibroblastsFoundationsGenerationsGeneticGenetically Engineered MouseHumanHydroxyeicosatetraenoic AcidsImmunoglobulin Class SwitchingImpaired wound healingIn VitroInflammatoryKnock-in MouseKnock-outKnockout MiceLaboratoriesLinkLipidsLipoxygenaseLiquid substanceMediatingMetabolismMethodsModelingMolecularMolecular BiologyMusOutcomePathologyPatientsPhasePhenotypePhosphatidylinositol 4,5-DiphosphatePhosphatidylinositolsPhospholipase A2Phospholipases APhysiologicalPhysiologyPlasmaPopulationPre-Clinical ModelProcessProductionProstaglandin-Endoperoxide SynthaseProstaglandinsRegulationRoleSignal PathwaySiteSphingolipidsTechnologyTestingTherapeuticTissuesVariantceramide 1-phosphateceramide kinasechronic wounddecubitus ulcergenetic manipulationhealingin vivoinhibitorlipid mediatorlipidomicsmigrationmortalitymouse modelmultidisciplinarymutantneutrophilnew technologynon-healing woundsnovelpatient populationphosphatidylinositol phosphate, PtdIns(4,5)P2pre-clinicalresponseskin ulcersmall moleculesmall molecule inhibitorwoundwound healing
项目摘要
In recent years, new technological advancements in small molecule analyses (e.g., lipidomics) have
identified a biochemical manifestation of impaired wound healing: the development of an imbalance between
pro- and anti-inflammatory eicosanoids1-9. The synthesis of eicosanoids begins with the initial rate-limiting step,
the generation of arachidonic acid (AA) via the activity of a phospholipase A2 (PLA2)10-12. One of the major PLA2s
involved in this initial step is group IVA cytosolic PLA2 (cPLA2α)10-12, which the Chalfant laboratory demonstrated
is activated by direct binding to the sphingolipid, ceramide-1-phosphate (C1P)13-19. Employing newer lipidomic
technology, we discovered that C1P is temporally regulated and specifically increases in the inflammatory phase
of human wound healing5. To evaluate C1P-induced eicosanoids in wound healing, we created a knock-in mouse
with the C1P site in cPLA2 ablated (KI). Our preliminary data show that KI mice, unlike the wild-type (WT) and
cPLA2 knockout (KO) mice, exhibit dramatically enhanced wound healing. These beneficial effects were linked
to the loss of inflammatory prostaglandins (e.g., cyclooxygenase (COX)-derived PGE2) and increased production
of specific lipid mediators (i.e., lipoxygenase (LOX)-derived 5-HETE), which induced significantly accelerated
migration of dermal fibroblasts and neutrophils. Importantly, in an initial study, we also found that high levels of
5-HETE in wound fluid from human pressure ulcers are linked to a better healing outcome. Thus, a balancing
act between LOX- and COX-derived lipid mediators is critical in the wound healing process.
Initial mechanistic studies also showed that relevant cellular phenotypes and variant production of
eicosanoid classes observed in KI cells are linked to a differential cellular localization of the C1P-ablated mutant
cPLA2 via association with PIP2. The findings provide a foundation for the premise that, when cPLA2 is unable
to bind C1P, the enzyme becomes free to associate with other lipid regulators (e.g., PIP2) that drive the
production of specific LOX-derived eicosanoids (e.g., 5- HETE). This mechanism is supported by our preliminary
in vitro studies showing that C1P blocks the activation of cPLA2α by PIP2. As LOX and COX products are both
cPLA2-dependent, but temporally contrast in their biosynthesis20.21, our data suggest that an overlooked
complexity in cPLA2 regulation exists in response to inflammatory agonists. Thus, we hypothesize that the
enhanced wound healing of pressure ulcers will reflect a novel “lipid-class switch” producing pro-healing
eicosanoids involving the complex, antagonistic regulation of cPLA2 by C1P and PIP2 metabolism. We also
hypothesize that aging humans, who display ineffective wound healing, will have ulcerative wounds lacking
these pro-healing lipid mediators, and a lipid signature will act as biomarker of healing outcome. To test these
hypotheses, we will employ a multi-disciplinary team, novel genetic mouse models, and “state of the art”
lipidomics and molecular biology technologies to explore the underlying mechanisms and bioactive lipids
associated with aging and the non-healing of ulcerative wounds.
近年来,小分子分析的新技术进步(例如,脂质组学)有
确定了受损伤口愈合的生化表现:
促炎和抗炎类二十烷酸1 -9。类二十烷酸的合成从初始限速步骤开始,
通过磷脂酶A2(PLA 2)的活性产生花生四烯酸(AA)10-12。主要PLA 2之一
参与这一初始步骤的是IVA组细胞质PLA 2(cPLA 2 α)10-12,Chalfant实验室证明了这一点
通过与鞘脂神经酰胺-1-磷酸(C1 P)13-19直接结合而激活。采用新的脂质组学
技术,我们发现,C1 P是时间调节,特别是在炎症阶段增加
人类伤口愈合5.为了评估C1 P诱导的类花生酸在伤口愈合中的作用,我们建立了一个敲入小鼠,
其中cPLA 2中的C1 P位点被切除(KI)。我们的初步数据表明,KI小鼠,不像野生型(WT)和
cPLA 2 β敲除(KO)小鼠表现出显著增强的伤口愈合。这些有益的影响是联系在一起的
导致炎性前列腺素的损失(例如,环氧合酶(考克斯)衍生的PGE 2)和增加的产生
特异性脂质介质(即,脂氧合酶(LOX)衍生的5-HETE),其诱导显著加速的
真皮成纤维细胞和中性粒细胞的迁移。重要的是,在最初的研究中,我们还发现,高水平的
5-来自人类压疮的伤口液中的HETE与更好的愈合结果有关。因此,平衡
LOX-和COX-衍生的脂质介质之间的作用在伤口愈合过程中至关重要。
初步的机制研究还表明,相关的细胞表型和变异体的产生,
在KI细胞中观察到的类二十烷酸类与C1 P消融突变体的差异细胞定位有关
cPLA 2通过与PIP 2结合而表达。这些发现为以下前提提供了基础:当cPLA 2不能
为了结合C1 P,酶变得自由地与其它脂质调节剂(例如,PIP 2)驱动
产生特异性LOX衍生的类二十烷酸(例如,5-HETE)。这一机制得到了我们初步的支持。
体外研究显示C1 P阻断PIP 2对cPLA 2 α的激活。由于LOX和考克斯产品都是
cPLA 2 β依赖性,但在其生物合成中存在时间对比20.21,我们的数据表明,
cPLA 2 β调节的复杂性存在于对炎性激动剂的应答中。因此,我们假设
压力性溃疡伤口愈合的增强将反映一种新的“脂质类开关”,
类花生酸涉及C1 P和PIP 2代谢对cPLA 2 β的复杂拮抗调节。我们也
假设显示无效伤口愈合的老年人将具有缺乏
这些促愈合脂质介质和脂质标记将作为愈合结果的生物标志物。测试这些
假设,我们将采用多学科的团队,新的遗传小鼠模型,和“最先进的”
脂质组学和分子生物学技术,探讨潜在的机制和生物活性的脂质
与衰老和溃疡性伤口的不愈合有关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHARLES E. CHALFANT其他文献
CHARLES E. CHALFANT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHARLES E. CHALFANT', 18)}}的其他基金
iPLA2beta-mediated alternative splicing and beta-cell death in type 1 diabetes
iPLA2beta 介导的 1 型糖尿病中的选择性剪接和 β 细胞死亡
- 批准号:
10594556 - 财政年份:2021
- 资助金额:
$ 45.72万 - 项目类别:
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
cPLA2α在类二十烷酸生物合成和伤口愈合中的作用和机制调节
- 批准号:
10614111 - 财政年份:2021
- 资助金额:
$ 45.72万 - 项目类别:
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
cPLA2α在类二十烷酸生物合成和伤口愈合中的作用和机制调节
- 批准号:
10156764 - 财政年份:2021
- 资助金额:
$ 45.72万 - 项目类别:
The role and mechanistic regulation of cPLA2alpha in eicosanoid biosynthesis and wound healing
cPLA2α在类二十烷酸生物合成和伤口愈合中的作用和机制调节
- 批准号:
10318663 - 财政年份:2021
- 资助金额:
$ 45.72万 - 项目类别:
iPLA2beta-mediated alternative splicing and beta-cell death in type 1 diabetes
iPLA2beta 介导的 1 型糖尿病中的选择性剪接和 β 细胞死亡
- 批准号:
10554009 - 财政年份:2021
- 资助金额:
$ 45.72万 - 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
9763685 - 财政年份:2019
- 资助金额:
$ 45.72万 - 项目类别:
相似海外基金
Epigenetic Age Acceleration Impacts Racial and Neighborhood Disparities in Chronic Low Back Pain
表观遗传年龄加速影响慢性腰痛的种族和社区差异
- 批准号:
10431156 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease
镰状细胞病的表观遗传年龄加速和精神神经症状
- 批准号:
10594523 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Early Life Cardiovascular Disease Risk Factors, Epigenetic Age Acceleration, and Alzheimer's Disease Related Brain Health
生命早期心血管疾病危险因素、表观遗传年龄加速和阿尔茨海默病相关的大脑健康
- 批准号:
10706044 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
The pathway from prenatal pregnancy-specific anxiety to offspring ADHD through epigenetic age acceleration DNA methylation and moderators to target intervention: Partner social support
通过表观遗传年龄加速 DNA 甲基化和调节因子从产前妊娠特异性焦虑到后代 ADHD 的途径:伴侣社会支持
- 批准号:
475968 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Studentship Programs
Epigenetic Age Acceleration and Psychoneurological Symptoms in Sickle Cell Disease
镰状细胞病的表观遗传年龄加速和精神神经症状
- 批准号:
10449461 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Functional genetic analysis of epigenetic age acceleration and the regulatory landscape of the methylome
表观遗传年龄加速的功能遗传分析和甲基化组的调控景观
- 批准号:
10674263 - 财政年份:2022
- 资助金额:
$ 45.72万 - 项目类别:
Perinatal Maternal Anxiety and Offspring ADHD Symptoms: Mediation Through Epigenetic Age Acceleration DNA Methylation
围产期母亲焦虑和后代 ADHD 症状:通过表观遗传年龄加速 DNA 甲基化进行调节
- 批准号:
467256 - 财政年份:2021
- 资助金额:
$ 45.72万 - 项目类别:
Studentship Programs
CAREER: Understanding the Role of Cu-Containing Secondary Phase Particles in Enhancing the Resistance to the Environmental Acceleration to Fatigue in Age-Hardenable Al Alloys
事业:了解含铜第二相颗粒在增强时效硬化铝合金的环境加速疲劳抵抗力方面的作用
- 批准号:
1943870 - 财政年份:2020
- 资助金额:
$ 45.72万 - 项目类别:
Continuing Grant
Breast Cancer Risk Factors and Epigenetic Age Acceleration
乳腺癌危险因素和表观遗传年龄加速
- 批准号:
10614228 - 财政年份:2020
- 资助金额:
$ 45.72万 - 项目类别:
The Clock is Ticking: Epigenetic Age Acceleration as a Biomarker of Uterine Function in Pregnancy
时钟在滴答作响:表观遗传年龄加速作为妊娠期子宫功能的生物标志物
- 批准号:
10630244 - 财政年份:2020
- 资助金额:
$ 45.72万 - 项目类别:














{{item.name}}会员




